Physician profile
Daniel Quon
NPI 1730346925
$17,740.49
in general payments reported to CMS, 2019-2025
34 companies · $3,554 in 2025
The $3,554 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,952 · 2020: $1,642 · 2021: $2,485 · 2022: $2,887 · 2023: $2,445 · 2024: $2,776 · 2025: $3,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,572 · Entertainment: $185 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,572.02 |
| Entertainment | $184.59 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $2,867.42 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $2,196.43 | 2022-2025 | Miebo, Infuse, Xiidra |
| Coopervision INC. | $1,301.94 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,101.78 | 2019-2025 | Eysuvis, Tryptyr, Wavelight Ex500 Excimer Laser |
| Oyster Point Pharma, INC. | $1,086.45 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $921.83 | 2020-2022 | |
| Glaukos Corporation | $908.80 | 2020-2025 | Istent Infinite, Idosetr |
| Dompe US, INC. | $868.07 | 2021-2025 | Oxervate |
| Biotissue Holdings INC. | $696.96 | 2020-2025 | |
| Johnson & Johnson Vision Care, INC. | $660.62 | 2019-2025 | Acuvue |
| Aerie Pharmaceuticals, INC. | $508.88 | 2020-2021 | |
| Shire North American Group INC | $504.79 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $482.81 | 2024-2025 | Xdemvy |
| Visioneering Technologies, INC. | $481.13 | 2019-2025 | |
| Allergan, INC. | $421.89 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $413.48 | 2019-2021 | |
| Harrow Eye, LLC | $354.90 | 2024-2025 | Vevye, Natacyn |
| Lumenis Be INC | $354.49 | 2023-2024 | Optilight, M22 |
| Optos, INC. | $268.23 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $240.29 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $208.32 | 2019 | |
| Thea Pharma INC. | $140.69 | 2023-2025 | Iyuzeh |
| Maculogix, INC. | $130.67 | 2020 | |
| Abbvie INC. | $123.95 | 2022 | |
| Abb Con-Cise Optical Group LLC | $117.17 | 2020-2023 | Contact Lens, Spectacle Lenses |
| Novartis Pharmaceuticals Corporation | $109.22 | 2021-2023 | |
| Optovue, INC. | $100.00 | 2019 | |
| Visionix USA, INC | $41.67 | 2022 | |
| Lumenis, INC | $28.88 | 2021 | |
| Amgen INC. | $22.08 | 2025 | Tepezza |
| Alcon Research LLC | $21.88 | 2019 | |
| Eyevance Pharmaceuticals LLC | $21.44 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oasis Medical, INC. | $13.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Quon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.